1. Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer 
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP 
CHEST 
Volume 128, Issue 6, Pages (December 2005)
DOI: /chest
Copyright © 2005 The American College of Chest Physicians Terms and Conditions

2. Figure 1
EGFR signaling pathway Akt = anti-apoptotic downstream cellular kinase; PI3K = phosphatidylinositol 3 kinase; PKC = protein kinase C; Grb2 = growth factor receptor bound protein-2; Sos = son of sevenless; MAPK = mitogen-activated protein kinase.
CHEST  , DOI: ( /chest )
Copyright © 2005 The American College of Chest Physicians Terms and Conditions

3. Figure 2 Rates of symptom improvement in the IDEAL trials.2526
CHEST  , DOI: ( /chest )
Copyright © 2005 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Rate of symptom improvement from onset of medication for patients who experienced improvement in the IDEAL-2 trial.26
CHEST  , DOI: ( /chest )
Copyright © 2005 The American College of Chest Physicians Terms and Conditions

5. Figure 4
Association of symptom improvement and survival in the IDEAL trials
CHEST  , DOI: ( /chest )
Copyright © 2005 The American College of Chest Physicians Terms and Conditions